Original peer-reviewed research & reviews #HeartSuccess @HFSA @JHeartFailureS @ElsevierConnect Co-EIC: @robmentz & @dranulala YouTube: tinyurl.com/jcf123
- Tweets 1,689
- Following 239
- Followers 9,107
- Likes 1,482
📝Editorial perspective: The DCD juggernaut continues!
As DCD moves from innovation to infrastructure, success must be measured beyond outcomes. Ethical stewardship, transparency, cost-effectiveness & preservation of public trust are critical to its future.
🧵👇
1
1
3
251
🚨New Science Alert!
🫀DCD heart transplantation has expanded rapidly nationwide to more centers & higher-risk recipients. Yet graft failure, mortality & other early outcomes remained stable.
This UNOS analysis supports the robustness & scalability of DCD.
🧵👇
2
5
11
1,155
📝 Editorial perspective: Structural objectivity ≠ moral objectivity.
Clear allocation rules make value judgments visible. They don't eliminate them. The next challenge: designing systems that reduce waitlist mortality, improve equity & sustain public trust.🫀
🧵👇
1
1
235
🌍How do countries decide who gets a donor heart first? This research article analyzes heart allocation policies globally.
Across 29 countries, 93% of allocation systems use urgency tiers. But how urgency, MCS priority, & exceptions are defined varies widely.
🧵👇
2
4
13
720
⏰Final Call
Submissions for JCF's Focus Issue: The New Frontier of Heart Function in Women close soon.
If your research advances women's cardiovascular health, now's the time to submit.
📅 Submissions close tomorrow, 9/15/26
bit.ly/4xQkPSR
#WomensHeartHealth
7
12
3,312
🫀 Heart transplantation is entering a new era!
This State-of-the-Art review explores advances reshaping the field: individualized LVAD vs transplant decisions, DCD & HCV+ donors, and new organ preservation strategies expanding the donor pool.
🔗 bit.ly/45xVQXm
🧵👇
2
13
27
2,087
What's next in heart transplantation? 🫀
Find out in the September Focus Issue on Innovations in Heart Transplantation.
Explore research and perspectives on new developments advancing heart transplantation care.
🔗 onlinejcf.com/current
#HeartTransplantation #Cardiology
10
14
3,430
📝 Editorial perspective
Discordance between PAWP and LVEDP shouldn't simply lead us to discount LVEDP. Instead, the pressure difference may offer important clues to underlying pathology affecting left atrial function. 🫀
🔗 bit.ly/4ibdM1p
@MicheleEmdin
5
6
290
🚨New science alert!
PAWP or LVEDP ... which better predicts outcomes?
Using simultaneous invasive hemodynamics at rest & during exercise, this study found that PAWP better reflected hemodynamic abnormalities & predicted adverse HF outcomes. 🫀
🔗 bit.ly/4x64Z5K
1
9
19
1,865
⏳ The deadline is approaching.
JCF is still accepting submissions for the Focus Issue: The New Frontier of Heart Function in Women.
If your research advances women's cardiovascular health, we encourage you to submit by 9/15/26.
bit.ly/4xQkPSR
3
3
614
🧬Precision medicine begins with a diagnosis.
In the largest real-world study to date, only 1.05% of patients with cardiomyopathy underwent genetic testing and just 7% received genetic counseling. Implementation — not evidence — remains the challenge.
🔗 bit.ly/4qpMbvF
2
7
506
📝 Editorial perspective
suPAR may represent more than prognostic information; it may identify an inflammatory pathway not addressed by current GDMT. The next frontier may be targeting residual inflammatory risk in HF. 🧬🫀
🔗 bit.ly/3TSKOJR
1
2
118
🫀🧬 Is suPAR more than a biomarker?
In SOLOIST-WHF, higher baseline suPAR predicted worse HF outcomes, but sotagliflozin reduced events regardless of suPAR and did not lower suPAR levels — pointing to residual inflammatory risk.
🔗 bit.ly/4qjyrT0
1
5
10
949
📝 Editorial perspective
DCD heart transplantation shouldn't be limited to high-volume centers. With standardized procurement, appropriate infrastructure & shared expertise, broader adoption could reduce geographic disparities & improve access. 🫀
🔗 bit.ly/4658cGz
1
2
188
🫀Does transplant center volume influence DCD heart transplant outcomes?
This UNOS analysis found similar perioperative outcomes and short-term survival at high & low-volume centers, supporting the growing robustness & reproducibility of DCD transplantation.
🧵👇
3
1
6
797
🫀Is predicted heart mass still the best way to size-match donor hearts?
This Perspective questions PHM in the modern era, highlighting its limitations in obesity & calling for next-generation metrics that better reflect body composition & cardiac size.
bit.ly/45xRZtm
7
12
1,042
📝 Editorial perspective
The question isn't whether OOS heart tx should expand or disappear. It's how to give it structured legitimacy. Standardized criteria, transparency, and better data will be key to ensuring equitable organ allocation. 🫀
🔗 bit.ly/462hfbo
1
5
246
🫀Out-of-sequence heart transplantation remains uncommon. But it's growing.
This study found OOS allocation increased from 1.4% to 3.1%, was concentrated in a small number of OPOs & centers, & achieved similar 1-year survival to standard allocation.
🔗 bit.ly/4qhMFDS
1
7
17
1,191
Out now! The August issue of JCF is live.
Catch up on the latest research and insights in heart failure.
See what’s inside 👉 onlinejcf.com/current
#HeartFailure #Cardiology #HeartFailureResearch
2
9
687
Impact is built together. 🫀🌎
It’s the research shared. The mentorship given. The conversations started. The connections made across the global heart failure community.
At JCF, our Impact Factor reflects something much bigger: what we can accomplish together.
3
8
814
How reliable is urine sodium concentration during continuous IV diuresis?
This Brief Report found substantial temporal variability in urine sodium despite stable loop diuretic infusions, raising questions about its role in monitoring diuretic response.
🔗bit.ly/4wKoG2A
1
7
16
950
📝 Editorial perspective
As LVAD technology improves, the role of adjunctive aspirin may be changing.
Modern HM3 LVAD support may allow simpler antithrombotic strategies with less bleeding and no loss of efficacy. 🫀
🔗bit.ly/3TGod2X
3
2
368
New science alert! Do AF, diabetes, or obesity change the benefits of aspirin withdrawal after HM3 LVAD?💖
This ARIES-HM3 analysis says no. Bleeding decreased without increases in stroke or thrombosis, even in these higher-risk subgroups.🩸
🔗bit.ly/4gbLxhI
2
7
11
753
Hear from the guest editors leading The New Frontier of Heart Function in Women as they share their excitement for this upcoming focus issue.
📅 Submissions open through Sept. 15th: bit.ly/4fC1NZh
#WomensHeartHealth #HeartFailure #CallForPapers
2
10
12
1,109
🫀🤖 Digital twins may help transform HF care from reactive to anticipatory!
This JCF Perspectives article explores how patient-specific computational models or "digital twins" could enable earlier detection of instability and more personalized care.
🔗 bit.ly/3TMBHKp
4
12
711
Editorial perspective: Only 0.2% of hospitalized HF patients carried an ATTR-CM diagnosis. Diagnosed patients may represent just the tip of the iceberg.🧊
Earlier detection of subclinical disease could reshape outcomes and healthcare utilization.🫀
🔗 bit.ly/3S2tq4y
1
2
148
How great is the burden of ATTR-CM? 🫀
In this study using the GWTG-HF registry, patients with ATTR-CM had higher HF readmission rates and greater healthcare costs, despite similar adjusted mortality. Earlier diagnosis and treatment remain critical!
🔗 bit.ly/3RhHBCH
1
5
8
794
Can interatrial shunts help HFpEF?
This State-of-the-Art Review revisits atrial shunt therapy, highlighting how phenotyping, invasive exercise hemodynamics & pulmonary vascular assessment may identify responders while avoiding harm in nonresponders.
🔗 bit.ly/45pzqY5
2
7
14
4,161
⭐️Editorial perspective: Can implantable IVC sensing transform HF care?❤️
The NORM Score may enable earlier congestion detection, patient self-management & proactive intervention. Success will depend on validation, implementation, pt selection & stakeholder buy-in.
🧵👇
1
2
249
Can we detect worsening HF before symptoms develop?📡❤️
A novel personalized congestion score derived from an IVC sensor predicted worsening HF events w/92.6% sensitivity & correlated with NT-proBNP levels. Early detection may enable more proactive HF management.
🧵👇
2
9
23
1,315
Sleep apnea & HFpEF have a bidirectional relationship.
Shared mechanisms - intermittent hypoxia, inflammation, sympathetic activation & HTN - may contribute to worse remodeling & outcomes. The editorial calls for routine screening & earlier treatment.
🔗onlinejcf.com/article/S1071-…
2
267
Could sleep apnea be a key driver of adverse outcomes in HFpEF? 😴❤️🩹
In a PARAGON-HF analysis, patients with SA had greater LV remodeling, worse BiV strain & 57% ⬆️risk of HFH or CV death. SA may represent an important, modifiable HFpEF phenotype.
🔗onlinejcf.com/article/S1071-…
2
5
14
1,262
Editorial perspective
Quadruple GDMT remains underutilized. Even when achieved, substantial residual risk persists. Greene & Butler argue that vericiguat's safety, tolerability & ease of use make it an attractive option as part of "quintuple therapy".
onlinejcf.com/article/S1071-…
3
14
13,053
How is vericiguat being used in real-world HFrEF care? ❤️🩹
In a study of >5,100 US patients following a worsening HF event, only ~36% reached the target 10 mg dose. Patients already receiving robust GDMT were more likely to achieve target dosing. 💊
🔗 onlinejcf.com/article/S1071-…
1
2
9
1,021
🫀 The July edition of JCF is here!
Featuring the latest perspectives and studies on heart failure and patient care.
🔗 Read the full issue: onlinejcf.com/current
6
12
829
📣Call for Papers:
JCF is accepting submissions for our focus issue: The New Frontier of Heart Function in Women.
Research spanning the female lifespan, from reproductive health to HFpEF, prevention, and heart failure is encouraged.
Submit by 9/15/26: bit.ly/4xQkPSR
1
7
8
2,932
Can LVADs do more than support circulation?
This JCF Ignite! article explores whether LVAD-mediated unloading can promote reverse remodeling and myocardial recovery, and whether some patients might benefit from LVAD therapy as a bridge to regeneration.
🔗bit.ly/3S0UHEj
1
9
19
1,215
Editorial perspective: Palliative care is not just end-of-life care. This editorial argues for integrating symptom management, shared decision-making & GoC discussions earlier in advanced HF, making palliative care a core component of longitudinal HF care. bit.ly/4oltKXL
1
222
How should palliative care fit into advanced HF care?
The HeartPal program embedded palliative care within an advanced heart disease service, resulting in earlier referrals, more GoC discussions, fewer late referrals & reduced in-hospital deaths.
bit.ly/3S4btlS
1
6
14
1,541
🚨HF-CS is now more common than AMI-CS.
This State-of-the-Art Review examines how microaxial flow pumps are reshaping HF-CS care through LV unloading, prolonged support, hemodynamic-guided management, and bridge-to-recovery/transplant strategies. 🫀📊
🔗 bit.ly/4ez3oye
8
29
2,488
🚨 What is the optimal MAP target in AMI-CS? This meta-analysis found no mortality benefit with higher MAP targets vs lower targets. 📊
The findings challenge a "higher is better" approach & highlight the need for individualized perfusion goals. ❤️🩹
🔗 bit.ly/4vL6dSW
3
9
1,373
📢 Call for Papers: The New Frontier of Heart Function in Women.
Guest Editors Drs. Anuradha Lala, Martha Gulati, Novi Yanti Sari, and Diana de Oliveira-Gomes will lead this issue, publishing in February '27.
Categories & topic areas: bit.ly/4vjovuq
Submit by Sept. 15
9
16
11,410
Editorial perspective 📝
SURPASS highlights the promise of Impella 5.5 as a bridge to recovery, transplant, or durable LVAD. But important questions remain!
Patient selection, timing, & support strategy may be just as important as the device itself.
🔗bit.ly/4avfPsr
1
1
660
New science 🚨: Impella 5.5 for HF-related cardiogenic shock 🫀
In the SURPASS registry (n=444), survival to discharge was 75% overall & 86.5% with Impella 5.5 alone. Patients bridged to transplant/LVAD had excellent outcomes, with >93% survival.
🔗bit.ly/4ecprJZ
1
7
24
1,997
We are proud of the progress reflected in this year’s Impact Factor of 9.9, but even more proud of what all of this represents.
A heartfelt THANK YOU to our entire JCF Family. Your engagement as authors, reviewers, readers, and mentors continues to drive this collective success.
14
36
18,309
🫀 Infiltrative & inflammatory cardiomyopathies share common pathways of dysfunction. Advanced imaging is shifting from structure→biology. Probing inflammation, microvascular dysfunction, and energetics to refine diagnosis and guide precision HF care.
bit.ly/4v2Oi9I
4
7
678
Last call! 🚨 Submissions close today for JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. Don’t miss the opportunity to contribute at this defining moment in HF care. 🫀
bit.ly/4kJl5gf
#HeartFailure #AIinHealthcare #CallForPapers
1
5
676
What's new in heart failure research?
Find out in the June edition of JCF, featuring expert perspectives advancing our understanding of heart failure and informing patient care.
Read the full issue: onlinejcf.com/current
2
6
10
1,058
Time is running out to submit to JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture.
If your work advances responsible innovation in HF care, now is the time to contribute.⌛
🗓️ Deadline: June 15th, 2026
bit.ly/4kJl5gf
#AIinHealthcare
1
4
13
2,161
In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%).
Benefits on CV outcomes were consistent across kidney function, even in advanced CKD.
Improves not just CV outcomes but has renal benefits🫀🧪
bit.ly/3Q2hhf1
13
19
2,129